Nausheen Ahmed
Overview
Explore the profile of Nausheen Ahmed including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
87
Citations
519
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
11.
Shahzad M, Khan M, Amin M, Sarfraz Z, Zulfiqar F, Qasim H, et al.
Transpl Immunol
. 2024 Oct;
87:102135.
PMID: 39368752
Background: Idiopathic Pneumonia Syndrome (IPS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT) is a life-threatening complication with high morbidity and mortality. IPS is thought to arise from damage caused by...
12.
Paul B, Anwer F, Raza S, Mammadzadeh A, Khasawneh B, Shatnawi S, et al.
Cancers (Basel)
. 2024 Sep;
16(17).
PMID: 39272795
The use of 4-drug induction regimens for treatment naïve newly diagnosed multiple myeloma (NDMM) is associated with improved depth of response and progression-free survival (PFS). However, head-to-head trials of 4-drug...
13.
Goel U, Dima D, Davis J, Ahmed N, Shaikh H, Lochner J, et al.
Eur J Haematol
. 2024 Aug;
113(6):817-823.
PMID: 39189919
Clinical trials evaluating chimeric antigen receptor (CAR) T-cell therapy in relapsed/refractory multiple myeloma (RRMM) have typically excluded patients with AL amyloidosis. As a result, there are limited data on the...
14.
Ahmed N, Wesson W, Lutfi F, Porter D, Bachanova V, Nastoupil L, et al.
Blood Adv
. 2024 Jul;
8(20):5346-5354.
PMID: 39042880
CD19-directed chimeric antigen receptor T-cell (CAR T) therapies, including axicabtagene ciloleucel (axi-cel), tisagenlecleucel (tisa-cel), and lisocabtagene maraleucel (liso-cel), have transformed the treatment landscape for B-cell non-Hodgkin lymphoma, showcasing significant efficacy...
15.
Pophali P, Fein J, Ahn K, Allbee-Johnson M, Ahmed N, Awan F, et al.
Blood Adv
. 2024 Jul;
8(20):5290-5296.
PMID: 38985302
T-cell/histiocyte-rich large B-cell lymphoma (THRLBCL) is a rare histologic variant of LBCL. Limited data regarding CD19-directed chimeric antigen receptor T-cell (CART) therapy in relapsed/refractory (R/R) THRLBCL suggest poor efficacy. We...
16.
Shadman M, Ahn K, Kaur M, Lekakis L, Beitinjaneh A, Iqbal M, et al.
Blood Cancer J
. 2024 Jul;
14(1):108.
PMID: 38977682
In patients with relapsed DLBCL in complete remission (CR), autologous hematopoietic cell transplantation (auto-HCT) and CAR-T therapy are both effective, but it is unknown which modality provides superior outcomes. We...
17.
18.
Khaliq A, Wesson W, Logan E, Tabak C, Mushtaq M, Lin T, et al.
Clin Lymphoma Myeloma Leuk
. 2024 Jun;
24(10):e344-e349.
PMID: 38910060
Introduction: Existing literature suggests that women are significantly underrepresented in the field of hematology-oncology. Women make up 35.6% of hematologists and data on females as site investigators for pivotal trials...
19.
Wesson W, Dima D, Suleman N, Saif M, Tabak C, Logan E, et al.
Transplant Cell Ther
. 2024 Jun;
30(9):876-884.
PMID: 38871056
BCMA-directed chimeric antigen receptor T-cell (CAR T) therapies, including idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel), have transformed the treatment landscape for relapsed-refractory multiple myeloma (RRMM), offering remarkable efficacy with...
20.
Shahzad M, Amin M, Bellman P, Al-Ramahi J, Noor J, Vyas A, et al.
Transfusion
. 2024 Jun;
64(8):1402-1406.
PMID: 38847196
Background: Nivestym, a biosimilar granulocyte colony-stimulating factor (G-CSF) to the originator filgrastim (Neupogen), is now being used for the mobilization of peripheral blood stem cells (PBSC) in allogeneic hematopoietic stem...